DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Brian Wu, MD candidate, Keck School of Medicine, Los Angeles, USA. DermNet New Zealand Editor in Chief: Hon A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. December 2016.
Autoimmune polyglandular syndrome type 2 (APS2) is the most common of the immunoendocrinopathy syndromes.
APS2 is also known as Schmidt syndrome.
APS2 is inherited in an autosomal dominant pattern; that is, an abnormal gene from one parent can cause disease and this happens even when the matching gene from the other parent is normal. A parent with an autosomal dominant condition has a 50% chance of having a child with the condition.
Researchers theorise that APS2 develops when a person with genetic susceptibilities is exposed to an autoimmune trigger. Initially, autoimmune activity is asymptomatic. Progressive organ damage and inflammatory infiltration occur over time.
The signs and symptoms of APS2 vary depending on the specific clinical manifestations seen in an individual; they may include:
APS2 is diagnosed in an individual who has multiple autoimmune diseases. Tests used to diagnose APS2 may include:
Other tests may include gonadotropin levels, thyroid tests (thyroid-stimulating hormone [TSH], triiodothyronine [T3] and thyroxine [T4]), plasma renin activity, serum electrolytes, fasting blood glucose and a complete blood count.
The treatment for APS2 depends upon which organs are affected, and may include:
The outlook for APS2 is variable and depends upon which specific organs or glands become affected by the syndrome.
See the DermNet NZ bookstore.
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.